Work

Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021, Pages 676-680]

Year: 2022

Type: erratum

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2022.11.010

Authors: Rodney P. Rocconi, Bradley J. Monk, Adam Walter, Thomas J. Herzog, Evanthia Galanis, Luisa Manning, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Phylicia Aaron, Neil Senzer, Robert L. Coleman, John Nemunaitis

Institutions: University of South Alabama, Arizona Oncology, ProMedica, University of Cincinnati, University of Cincinnati Medical Center, Mayo Clinic, Gradalis (United States), The US Oncology Network

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310184833

Cites:

Cited by:

Related to: 10